Abstract：
OBJECTIVE: To compare the quality of life (QoL) in the same patients first treated with botulinum toxin A (BTA) injections for neurogenic detrusor overactivity (NDO) and then with bladder augmentation (BA).
METHODS: Retrospective study of patients who had BA after BTA treatment between January 2012 and December 2022. Qualiveen Short Form questionnaires and a 7-level Likert/PGI-I scale to answer the question \"How would you describe your quality of life after surgery compared to when you felt your best with BTA injections?\" were collated and analyzed.
RESULTS: Fifty-two BAs for neurogenic bladder (NDO or low compliance) were performed in patients with a median age of 43years [33; 52] previously treated with BTA. After a median follow-up of 33.5 [13.8; 54.3] months, the median Qualiveen-SF global score after BA was significantly higher than that obtained at best BTA efficacy (1.63 [1; 2.63] vs. 2.63 [1.88; 3], P=0.012), as were the scores for the fear, constraints/restrictions and limitations/inconvenience domains. The median PGI-I score was +3 [2; 3] (truly better QoL) and 85.4% of patients reported a QoL after BA superior to the best QoL under BTA.
CONCLUSIONS: BA provides a greater range of QoL improvement than BTA injection for patients who have experienced both treatments. Long-lasting effects and absence of need to perform iterative retreatment were the main reasons.
METHODS:
METHODS: Retrospective study of patients who had BA after BTA treatment between January 2012 and December 2022. Qualiveen Short Form questionnaires and a 7-level Likert/PGI-I scale to answer the question \"How would you describe your quality of life after surgery compared to when you felt your best with BTA injections?\" were collated and analyzed.
RESULTS: Fifty-two BAs for neurogenic bladder (NDO or low compliance) were performed in patients with a median age of 43years [33; 52] previously treated with BTA. After a median follow-up of 33.5 [13.8; 54.3] months, the median Qualiveen-SF global score after BA was significantly higher than that obtained at best BTA efficacy (1.63 [1; 2.63] vs. 2.63 [1.88; 3], P=0.012), as were the scores for the fear, constraints/restrictions and limitations/inconvenience domains. The median PGI-I score was +3 [2; 3] (truly better QoL) and 85.4% of patients reported a QoL after BA superior to the best QoL under BTA.
CONCLUSIONS: BA provides a greater range of QoL improvement than BTA injection for patients who have experienced both treatments. Long-lasting effects and absence of need to perform iterative retreatment were the main reasons.
METHODS:
摘要：
目的：比较首次注射肉毒杆菌毒素A（BTA）治疗神经性逼尿肌过度活动（NDO）后再进行膀胱扩张（BA）治疗的相同患者的生活质量（QoL）。
方法：回顾性研究2012年1月至2022年12月BTA治疗后BA患者。Qualiveen简短形式问卷和7级Likert/PGI-I量表回答以下问题：“与BTA注射效果最佳时相比，您如何描述手术后的生活质量？”进行了整理和分析。
结果：在先前接受过BTA治疗的中位年龄为43岁[33;52]的患者中，对神经源性膀胱（NDO或低顺应性）进行了52次BA治疗。在中位随访33.5[13.8;54.3]个月后，BA后的Qualiveen-SF总体评分中位数显着高于最佳BTA疗效（1.63[1;2.63]vs.2.63[1.88;3]，p=0.012),恐惧的分数也是如此，约束/限制和限制/不便域。中位PGI-I评分为+3[2;3]（真正更好的QoL），85.4%的患者报告BA后QoL优于BTA下的最佳QoL。
结论：BA提供了比BTA注射更大范围的QoL改善经历了两种治疗的患者。长期的效果和不需要进行迭代再治疗是主要原因。
方法：回顾性研究2012年1月至2022年12月BTA治疗后BA患者。Qualiveen简短形式问卷和7级Likert/PGI-I量表回答以下问题：“与BTA注射效果最佳时相比，您如何描述手术后的生活质量？”进行了整理和分析。
结果：在先前接受过BTA治疗的中位年龄为43岁[33;52]的患者中，对神经源性膀胱（NDO或低顺应性）进行了52次BA治疗。在中位随访33.5[13.8;54.3]个月后，BA后的Qualiveen-SF总体评分中位数显着高于最佳BTA疗效（1.63[1;2.63]vs.2.63[1.88;3]，p=0.012),恐惧的分数也是如此，约束/限制和限制/不便域。中位PGI-I评分为+3[2;3]（真正更好的QoL），85.4%的患者报告BA后QoL优于BTA下的最佳QoL。
结论：BA提供了比BTA注射更大范围的QoL改善经历了两种治疗的患者。长期的效果和不需要进行迭代再治疗是主要原因。
